NATICK, Mass., June 28 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed the results of a report from UBS Investment Research that ranked the Company number one in "Technology Strength" in a study of the intellectual property portfolios of medical device companies. The report, by UBS analysts Kenneth Weakley and Kristen Stewart, analyzed data from nearly 23,000 U.S. patents and 9,000 U.S. patent applications. Boston Scientific also ranked number one in the report's Current Impact Index. The report defines Technology Strength as a measure of a company's intellectual property power, while Current Impact Index is a measure of patent portfolio quality.
Highlights from the Report: * " ... patents are a critical component in protecting a company's innovations to assure the economic success of its research and development." * "History has shown that firms with the broadest, largest collection of intellectual property and R&D agendas tend to be more successful over the long run." * "Boston Scientific's patent portfolio has the highest technology strength ... " * "Boston Scientific's intellectual franchise will increase significantly with the addition of Guidant." * "The trends for Guidant in its pacemaker/ICD business, which saw a significant increase in the concentration of patent applications relative to its existing patent base, bode well for Boston Scientific, as it integrates the business and builds out its electrical engineering skills."
"Boston Scientific was built on the strength of its intellectual property," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "Our patent portfolio is one of the strongest in the industry and has fueled the tremendous growth we've experienced as a company. We are pleased that this strength has been recognized by UBS Investment Research. This recognition is a tribute to Boston Scientific's research and development team, who work everyday to bring new, innovative technology to our customers and their patients."
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com/.
This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, competitive offerings, integration of acquired companies, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.
CONTACT: Milan Kofol 508-650-8569 Investor Relations Boston Scientific Corporation Paul Donovan 508-650-8541 Media Relations Boston Scientific Corporation
SOURCE: Boston Scientific Corporation
CONTACT: Milan Kofol, Investor Relations, +1-508-650-8569 or Paul
Donovan, Media Relations, +1-508-650-8541, both of Boston Scientific
Web site: http://www.bostonscientific.com/